Speculating in Takeover Targets Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets

ULBI 5.780

-4.1%

3:57 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: richardred who wrote (428)	1/26/2005 9:08:32 AM
From: richardred	Read Replies (1) of 7254

BDX great earnings. BD Biosciences unit should be geared for another acquisition. Especially after the sale of the Clontech is completed. OLD SNIP-Franklin Lakes, NJ -- Monday, October 04, 2004 -- BD (Becton, Dickinson and Company) (NYSE: BDX) today announced that its Board of Directors had approved a plan to sell the Company's Clontech operation, a unit of BD Biosciences. "The plan to sell Clontech is a result of BD Biosciences' decision to focus its strategy on cell analysis, discovery labware and its new platforms of imaging and in vitro drug metabolism/toxicity testing," stated Edward J. Ludwig, Chairman, President and Chief Executive Officer. "This also allows us to direct our resources toward higher-growth opportunities in the pharmaceutical drug discovery arena."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next